Men with intermediate or high-risk localised prostate cancer should be given a
combination of radical radiotherapy and androgen deprivation therapy, rather than
radical radiotherapy or androgen deprivation therapy alone, recommends newly
updated guidance [publications.nice.org.uk] from the National Institute of Health
and Care Excellence (NICE), published today.
